CNMD  Conmed Corporation

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Market Cap.

1210.34B

Vuru Grade

37.57/100

Current Price

$43.50
+0.11 (+0.25%)

Growth Price

$31.81
Overvalued by 26.88%

Stability Price

$17.47
Overvalued by 59.84%

Company Metrics

  • P/E 83.65
  • P/S 1581.21
  • P/B 2.08
  • EPS 0.52
  • Cash ROIC 6.92%
  • Cash Ratio 0.61
  • Dividend 0.80 / 1.84 %
  • Avg. Vol. 148,779.00
  • Shares 27.86M
  • Market Cap. 1210.34B

Company Description

CONMED Corporation, a medical technology company, provides surgical devices and equipment for minimally invasive procedures and monitoring. The company's products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery, and endoscopic technologies. It offers arthroscopy products, including powered resection instruments, art... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

CONMED Corp.: Get Out
Seeking Alpha - Jan 25, 2017
Since the company consolidated its reporting in 2013, long term debt has grown rapidly at Conmed. For instance, during the period 2013 to the end of September 2016, revenue declined by about 5%, while long term indebtedness increased by 128%.
CONMED Corporation (CNMD) Moves Higher on Volume Spike for February 16
Equities.com - Feb 16, 2017
CONMED Corporation (CNMD) traded on unusually high volume on Feb. 16, as the stock gained 0.28% to close at $43.39. On the day, CONMED Corporation saw 470,026 shares trade hands on 2,268 trades. Considering that the stock averages only a daily ...
CONMED Corporation to Present at the Leerink Partners 6th Annual Global ...
Yahoo Finance - Jan 26, 2017
CONMED Corporation (CNMD) today announced that Curt R. Hartman, President and Chief Executive Officer, and Luke A. Pomilio, Chief Financial Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference at 2:30 p.m. ET on ...
CONMED Corporation Announces Fourth Quarter and Fiscal Year 2016 Financial Results
Yahoo Finance - Feb 1, 2017
Clearly, these successes were offset by ongoing challenges in domestic Orthopedics, where we believe we are taking the appropriate steps to drive improvement in this business over the coming quarters,” commented Curt R. Hartman, CONMED's President ...
CONMED CORPORATION (NASDAQ:CNMD) Files An 8-K Results of Operations and ... - Market Exclusive
CONMED Corporation (CNMD) Moves Lower on Volume Spike for February 02 - Equities.com
The CONMED Corporation (CNMD) Shares Sold by the Wells Fargo & Company MN
DailyQuint - 1 hour ago
Wells Fargo & Company MN decreased its stake in shares of CONMED Corporation (NASDAQ:CNMD) by 1.5% during the third quarter, Holdings Channel reports.
Folger Hill Asset Management LP Decreases Position in CONMED Corporation (CNMD)
The Cerbat Gem - Feb 17, 2017
CONMED Corporation logo Folger Hill Asset Management LP reduced its stake in shares of CONMED Corporation (NASDAQ:CNMD) by 31.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission.
The Conmed Corp. (CNMD) Stock Rating Decreased by the Zacks Investment Research - DailyQuint
CONMED Corporation (NASDAQ:CNMD) Analyst Recommendation - NewsDen
CONMED Corporation Announces Third Quarter 2016 Financial Results
Business Wire (press release) - Oct 27, 2016
Overall, we are pleased with a return to positive organic growth on a constant currency basis,” commented Curt R. Hartman, CONMED's President and Chief Executive Officer. “As we close out the year, we look to build upon the recent momentum across ...
CONMED Corporation Announces Second Quarter 2016 Financial Results
Business Wire (press release) - Jul 27, 2016
CONMED has a direct selling presence in 17 countries, and international sales constitute approximately 50% of the Company's total sales.
CONMED Corporation to Present at the JP Morgan Healthcare Conference
Business Wire (press release) - Dec 22, 2016
UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NASDAQ:CNMD) today announced that Curt R. Hartman, President and Chief Executive Officer, and Luke A. Pomilio, Chief Financial Officer, will present at the 35th Annual J.P.
Needham & Company LLC Reaffirms Buy Rating for CONMED Corporation (CNMD)
Sports Perspectives - Feb 7, 2017
CONMED Corporation logo Needham & Company LLC reiterated their buy rating on shares of CONMED Corporation (NASDAQ:CNMD) in a research note released on Thursday.
The Capital Research Global Investors Has $50104000 Stake in CONMED ... - DailyQuint
CONMED Corporation (CNMD) Expected to Earn Q1 2017 Earnings of $0.30 Per Share - Community Financial News
Growth Rate Assumed by Market

We did a reverse valuation to calculate the growth rate the market is assuming for CNMD to be considered fairly valued at its current market price. It's useful to compare this to the growth rate we're assuming for the Growth Price.

Future Free Cash Flow Growth Rate

This is the annual growth rate we've applied to calculate CNMD's Free Cash Flow for the next 10 years. To calculate it, we looked at several time periods of the last 10 years. Feel free to adjust it, but we limit the initial growth rate to 20% and slow it down over the years. Otherwise, long-term sustainability issues come into play.

Discount Rate

The discount rate is the annual rate of return an investor requires to take the risk of investing in a single stock. To account for that risk, this should be above 8-10%, as this is the avg. annual rate of return for the S&P500 over the past 100 years.

$43.50 Current Price

$31.81 Growth Price (DCF)

Overvalued by 26.88%


Growth Rate Assumed by Market: 26.34%


Future Free Cash Flow Growth Rate: 8.7%


Discount Rate: 15.0%


Show Free Cash Flow numbers

$17.47 Stability Price (EPV)

Overvalued by 59.84%


Discount Rate: 15.0%

$33.61 Book Price

Overvalued by 22.73%


Poor Cash Return on Invested Capital over the past 5 years

CNMD has been unable to consistently generate sufficient returns from its investments in buildings, projects and equipment. This could be due to poor management, lack of an economic moat or the capital intensive nature of the business.

CNMD has only created $6.92 of cash for every $100 invested.
Figures in USD. Fiscal year ends in December
20112012201320142015
Free Cash Flow 85.44M 73.67M 62.50M 49.77M 33.06M
divided by
Invested Capital 778.36M 938.23M 924.80M 915.91M 920.72M
Cash ROIC 10.98% 7.85% 6.76% 5.43% 3.59%

Poor Return on Equity over the past 5 years

CNMD has shown an inability to deliver strong results for shareholders. This could be due to poor management, CNMD operating in a highly competitive industry, or having a weak business in general.

CNMD has only generated $4.70 of Earnings for every $100 of Shareholders' Equity.
Figures in USD. Fiscal year ends in December
20112012201320142015
Net Income 752,000.00 40.48M 35.94M 32.19M 30.50M
divided by
Stockholders' Equity 573.07M 607.00M 606.32M 581.30M 585.07M
Return on Equity 0.13% 6.67% 5.93% 5.54% 5.21%

Excellent Business Performance over the past 10 years

CNMD has been able to maintain profitability in good times and bad. This could mean CNMD has an extremely strong business or has the ability to scale down costs when needed. This should be a fairly resilient business, but double check for future sustainability by looking at its Risk Factors in the Annual Report.

CNMD has created positive free cash flow for 9 or more of the past 10 years.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Free Cash Flow 42.68M 44.98M 25.27M 3.58M 23.51M 85.44M 73.67M 62.50M 49.77M 33.06M

Good Balance Sheet

CNMD's Total Assets double Total Liabilities. Its financial position is adequate. Remember to check Shareholders' Equity to see if it's stable or growing. It's one of the best measures of whether a company is creating value for shareholders.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Cash 3.83M 11.70M 11.81M 10.10M 12.42M 26.05M 23.72M 54.44M 66.33M 72.50M
Current Assets 249.88M 279.02M 294.26M 325.61M 350.19M 356.72M 346.19M 372.13M 381.15M 407.49M
Total Assets 861.57M 893.95M 931.66M 958.41M 985.77M 935.59M 1.08B 1.09B 1.10B 1.11B
Current Liabilities 75.21M 77.28M 74.91M 79.11M 179.87M 131.18M 122.51M 111.27M 115.96M 119.72M
Total Liabilities 421.22M 388.95M 399.93M 381.90M 399.21M 362.52M 477.46M 484.19M 516.90M 527.87M
Stockholder' Equity 440.35M 505.00M 531.73M 576.52M 586.56M 573.07M 607.00M 606.32M 581.30M 585.07M
Current Ratio 3.32 3.61 3.93 4.12 1.95 2.72 2.83 3.34 3.29 3.40
TL-to-TA 0.49 0.44 0.43 0.40 0.40 0.39 0.44 0.44 0.47 0.47

Consistent Reinvestment of Profits over the past 10 years

CNMD has consistently retained profits. This may put CNMD in a strong position to invest for the future, by buying new machinery, investing in R&D or a number of other options. By effectively using these earnings, CNMD can greatly improve their long-term economic picture.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Retained Earnings 247.43M 284.85M 327.47M 325.37M 354.02M 354.44M 377.91M 395.89M 406.15M 414.51M
Retained Earnings Growth - 15.13% 14.96% -0.64% 8.81% 0.12% 6.62% 4.76% 2.59% 2.06%

Highly Competitive Industry over the past 10 years

It's likely that CNMD is in an industry with low barriers to entry, spurring high competition. If Gross Margins are at least satisfactory, it's likely CNMD invests heavily in R&D and Sales, General & Administrative expenses.

Only $3.47 of every $100 of Revenue have been profit, on average over the past 10 years.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Net Income -12.51M 41.46M 44.56M 12.14M 30.35M 752,000.00 40.48M 35.94M 32.19M 30.50M
divided by
Revenue 646.81M 694.29M 742.18M 694.74M 713.72M 725.08M 767.14M 762.70M 740.06M 719.17M
Net Profit Margin -1.93% 5.97% 6.00% 1.75% 4.25% 0.10% 5.28% 4.71% 4.35% 4.24%

Strong Pricing Power over the past 10 years

CNMD has maintained substantial gross margins, suggesting that they have been able to set prices without consideration of the cost of goods sold. This potentially leaves flexibility in inflationary environments to raise prices on consumers and maintain profitability.

$51.63 of every $100 worth of sales have been Gross Profit, on average over the past 10 years.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Gross Profit 312.85M 349.13M 382.38M 337.33M 365.38M 374.93M 405.84M 412.42M 404.06M 381.70M
divided by
Revenue 646.81M 694.29M 742.18M 694.74M 713.72M 725.08M 767.14M 762.70M 740.06M 719.17M
Gross Margin 48.37% 50.29% 51.52% 48.56% 51.19% 51.71% 52.90% 54.07% 54.60% 53.08%

High Capital Intensity over the past 10 years

CNMD spends large amounts of capital buying new equipment or investing in new facilities to stay competitive. Over the long term, those costs may have to be fuelled by debt. Look at the growth of Shareholders' Equity to see if this strategy is having a positive or negative impact.

321.31% of Profits are being spent on Capital Expenditures, like Property, Plant, & Equipment, required to run the business.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Capital Expenditure 21.90M 20.91M 35.88M 21.44M 14.73M 17.55M 21.53M 18.45M 15.41M 15.01M
divided by
Net Income -12.51M 41.46M 44.56M 12.14M 30.35M 752,000.00 40.48M 35.94M 32.19M 30.50M
Capital Expenditure Ratio -175.06% 50.44% 80.52% 176.68% 48.55% 2,334.04% 53.19% 51.32% 47.87% 49.21%

No Dividend History over the past 10 years

CNMD has never distributed dividends or has recently suspended their dividend distribution.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Dividend Paid - - - - - - - - - -
divided by
Shares Outstanding 27.79M 28.99M 29.23M 29.14M 28.91M 28.63M 28.65M 28.11M 27.77M 27.86M
Dividend Paid Per Share - - - - - - - - - -
Price at Year End 23.12 23.32 23.08 23.18 26.53 25.67 27.47 42.48 44.96 44.36
Dividend Yield - - - - - - - - - -

History of Stock Buybacks over the past 10 years

CNMD has some history of delivering increased value for shareholders in the form of stock buybacks. These have helped improve financial metrics and increase each shareholders' relative ownership stake in the company, due to fewer shares outstanding and holding the same number of shares.
Figures in USD. Fiscal year ends in December
2006200720082009201020112012201320142015
Shares Outstanding 27.79M 28.99M 29.23M 29.14M 28.91M 28.63M 28.65M 28.11M 27.77M 27.86M
Stock Bought Back - -4.13% -0.81% 0.29% 0.80% 0.97% -0.07% 1.92% 1.24% -0.32%
Share your thoughts about CNMD

Sign Up or Log In to start contributing!


Discussion

Nothing here yet. Be the first to post!